10:27 AM EDT, 03/25/2024 (MT Newswires) -- Syros Pharmaceuticals ( SYRS ) said Monday it completed the enrollment of 190 people in a phase 3 trial assessing tamibarotene, which is intended to treat higher-risk myelodysplastic syndrome in patients with RARA gene overexpression.

The initial group of 190 people is needed to back the trial's complete response primary endpoint analysis, the company said, adding that it expects to release the complete response results by mid-Q4.

The primary endpoint is the complete response rate in the first 190 people enrolled in the study. The key secondary endpoint is the overall survival in 550 people. Enrollment is ongoing to reach the target of 550 people, the company said.

Price: 6.33, Change: +0.06, Percent Change: +0.96